Sida Cordifolia for Respiratory Complaints: The Alkaloid Behind the Tradition

Cough, asthma and nasal congestion sit near the top of every list of traditional indications for bala. This page asks a narrower question than the hub already answers: is there a real pharmacological reason a plant would ease breathing, and if so, which of its constituents is responsible? The hub’s central warning is about ephedrine and pseudoephedrine and the cardiovascular harm they cause — we are not repeating that case here. What this page adds is the rest of the chemistry: a second, structurally unrelated alkaloid family that this plant also contains, that also has real bronchodilator pharmacology behind it, and that changes how the respiratory tradition should be read.

The short version: Sida cordifolia is not chemically simple. It carries at least two distinct alkaloid classes capable of affecting the airway — the phenethylamines (ephedrine, pseudoephedrine) that the hub already covers in depth, and the quinazolines (vasicine, vasicinone, and a close relative isolated from this plant specifically). They are different molecules, from different biosynthetic pathways, with different safety profiles. Telling them apart is the actual content of the respiratory claim, and most marketing for this plant does not bother.

Table of Contents

  1. The Traditional Indication
  2. Two Alkaloid Families, Two Different Stories
  3. Ephedrine: A Real Bronchodilator, Already Covered — and Abandoned for a Reason
  4. Vasicine: Confirmed Present, and Richest in This Species
  5. Where the Bronchodilator Evidence for Vasicine Actually Comes From
  6. The Arithmetic: What a Traditional Root Dose Actually Delivers
  7. Sixty-Five Years of Trying to Turn Vasicine Into a Drug
  8. A Cross-Cultural Pattern: Ma Huang, Vasaka and Bala
  9. What This Means for a Reader With Asthma or a Cough
  10. Evidence Ledger for This Page
  11. Key Research Papers
  12. Connections

The Traditional Indication

Evidence tier: traditional use, well-documented and consistent across sources.

The hub’s Traditional Use section already places respiratory complaints among bala’s three main classical indication clusters, alongside musculoskeletal/neurological use and general debility. That consistency across independent classical sources — the plant shows up for cough, wheeze and breathlessness in text after text, not just one regional tradition — is itself a data point worth taking seriously. Traditional use is not proof of efficacy (a plant can be used for two thousand years and still not work, and the hub says so plainly), but a consistent, specific indication repeated across independent lineages is a different kind of signal than a vague, catch-all one. It is the kind of pattern worth asking “why this plant, for this complaint, specifically” about — and here, unusually for a traditional herb on this site, there is a concrete chemical answer.

Two Alkaloid Families, Two Different Stories

The hub’s Active Compounds section lists the plant’s alkaloid content in one paragraph: ephedrine, pseudoephedrine, vasicine, vasicinone, vasicinol, hypaphorine and betaine. It is worth pulling these apart by chemical family, because the family determines the pharmacology far more than the fact of being “an alkaloid” does.

This distinction matters because it is easy, and wrong, to treat “this plant has alkaloids” as a single fact with a single risk. It has (at least) two pharmacologically unrelated alkaloid stories running in parallel. The cardiovascular hazard belongs entirely to one of them.

Ephedrine: A Real Bronchodilator, Already Covered — and Abandoned for a Reason

Evidence tier: established human pharmacology (for ephedrine as a drug), no trial of the plant.

The hub’s own Respiratory Effects section already states the essential fact plainly: ephedrine is a genuine bronchodilator, used clinically for asthma for decades before selective beta-2 agonists like salbutamol replaced it, and abandoned specifically because its cardiovascular effects were unacceptable next to a drug that reaches the lung and mostly stays there. We are not re-arguing that here — see the hub for the full case series and meta-analysis data behind the cardiovascular warning. The point worth adding is historical and comparative: this is not a story unique to Ayurveda. Ephedrine-type alkaloids from Ephedra sinica (ma huang) were the basis of a parallel, independently-arrived-at respiratory tradition in Chinese medicine, reviewed comprehensively in Ephedrae herba: a comprehensive review of its traditional uses, phytochemistry, pharmacology, and toxicology (Zheng Q et al., Journal of Ethnopharmacology, 2023), with a 2026 follow-up specifically on the nervous-system pharmacology and neurotoxicity of ephedrine (Li J et al., American Journal of Chinese Medicine, 2026). Two unconnected traditional systems converged on the same class of molecule for the same complaint. That convergence is more evidence that the effect is pharmacologically real than any single tradition could establish alone — and it is also exactly why the same molecule causes the same cardiovascular problem wherever it turns up, whether the label says ma huang or bala.

Vasicine: Confirmed Present, and Richest in This Species

Evidence tier: direct phytochemical quantification (root material).

Vasicine and vasicinone are best known from Adhatoda vasica (Malabar nut, vasaka), where they are the compounds behind that plant’s long-standing use as a bronchodilator and expectorant — the hub already notes bala shares these alkaloids with vasaka. What the hub does not detail is that this is not merely a shared-genus assumption: it has been measured directly in Sida cordifolia root by high-performance liquid chromatography. Subramanya and colleagues quantified vasicine and vasicinone in the roots of eight Sida species side by side, and found Sida cordifolia had the highest vasicine content of all eight — 9.891 ± 0.495 µg per 100 mg of dried root — while a related species, Sida cordata, was richest in vasicinone (Subramanya MD et al., Ayu, 2016). A separate 2024 densitometric method confirmed vasicine and vasicinone among six specialised metabolites quantifiable across four Sida species and their congener Abutilon indicum (Rahate SP et al., Journal of Pharmaceutical and Biomedical Analysis, 2024 — also cited on the hub’s research list).

This is a genuinely different evidentiary situation from a borrowed-species claim. The compound is not merely assumed present by taxonomic proximity to vasaka — it has been measured, in the correct plant, in the correct part (root, the traditional preparation), at a higher concentration than in most of its own close relatives.

Where the Bronchodilator Evidence for Vasicine Actually Comes From

Evidence tier: animal and mechanistic pharmacology — almost entirely on Adhatoda vasica, not Sida cordifolia.

Here the picture becomes a genuine borrowed-evidence case, and it needs labelling as one (see the site’s evidence doctrine on species substitution). The foundational demonstration that vasicinone is a bronchodilator was published in Nature in 1959: Amin and Mehta isolated the alkaloid from Adhatoda vasica and showed its bronchodilator activity directly — A bronchodilator alkaloid (vasicinone) from Adhatoda vasica Nees (Amin AH, Mehta DR, Nature, 1959). Modern mechanistic work continues on the same source plant: a 2026 study found vasicine attenuates allergic asthma in a mouse model by suppressing mast-cell degranulation and Th2 inflammation through the FcεRI/Lyn–Syk/MAPK pathway (Qu L et al., Pharmaceuticals, 2026), and medicinal chemists have continued developing vasicinone-derived quinazoline compounds as candidate bronchodilators, most recently a 2025 pharmacokinetic, pharmacodynamic and toxicity evaluation of several synthetic analogues (Špulák M et al., Journal of Pharmacology and Experimental Therapeutics, 2025).

None of these studies used Sida cordifolia material. They establish that the molecule vasicine/vasicinone is a real bronchodilator with a defined receptor-independent mechanism (mast-cell stabilisation and airway smooth-muscle relaxation, distinct from the adrenergic mechanism of ephedrine) — but the demonstration is in the sister genus. Combined with the phytochemical section above, the honest summary is: the compound is confirmed present in Sida cordifolia root by direct assay, and the pharmacology of that same compound is well established — in a different, related plant. That is a stronger position than pure species substitution (where the compound itself is only assumed, not measured, in the plant being sold) and a weaker one than dedicated evidence (no bronchodilator assay has ever been run on Sida cordifolia extract itself, to our knowledge).

The Arithmetic: What a Traditional Root Dose Actually Delivers

Worth doing the calculation the hub’s own Dosage section sets up but does not carry through for vasicine specifically. The hub gives the traditional root-powder dose as roughly 3–6 g/day. At Subramanya’s measured concentration of 9.891 µg vasicine per 100 mg of root, that traditional dose delivers approximately:

That is a real, non-zero, measured exposure — and it is small in absolute terms, a few tenths of a milligram. We are not going to convert that into a claim about whether it is “enough” to produce a clinical bronchodilator effect, because no human pharmacokinetic or dose-response study of vasicine from any source has been published that we could check that claim against, and the animal-model doses used in the mechanistic papers above are not directly convertible to a human-equivalent figure without assumptions we cannot verify. What the arithmetic does establish is a useful, checkable contrast: this tiny root-decoction exposure to vasicine is orders of magnitude below the extract concentrations used in every pharmacology study cited above, all of which used purified compound or concentrated extract, not a few grams of simmered root. Whatever vasicine is doing in a traditional decoction, it is doing it at a dose far below anything that has actually been tested.

Sixty-Five Years of Trying to Turn Vasicine Into a Drug

Evidence tier: medicinal chemistry, drug-development history.

The vasicine/vasicinone bronchodilator mechanism has attracted sustained pharmaceutical interest since Amin and Mehta’s 1959 Nature paper — this is not a mechanism anyone dismissed. Synthetic quinazoline derivatives have been made and tested repeatedly: a novel quinazolin derivative with confirmed bronchodilator activity (Zabeer A et al., European Journal of Medicinal Chemistry, 2006), a series of dihydroimidazoquinazoline compounds evaluated as potential bronchodilators with structure-activity relationships worked out (Bahekar RH, Rao AR, Arzneimittel-Forschung, 2001), and the 2025 pharmacokinetic/toxicity evaluation already mentioned above. This is a real, decades-long medicinal chemistry program, not a fringe idea.

What is also true, and worth stating plainly per this site’s practice of naming a mechanism’s ceiling rather than only its promise: none of this research has produced an approved bronchodilator drug on the market. Sixty-five years of synthesis and animal pharmacology have not converted the vasicine scaffold into a marketed medicine, while the unrelated beta-2 agonist class (salbutamol, salmeterol and their relatives) became — and remains — the standard of care. That does not mean the mechanism is fake; a compound can fail to reach market for reasons that have nothing to do with whether it works (selectivity, manufacturing cost, patent timing, a competitor arriving first). But it does mean the honest ceiling on this evidence, even taken at its most favourable, is “a real and still-actively-researched mechanism that has not yet cleared the bar of a licensed medicine” — not “a proven alternative to an inhaler.”

A Cross-Cultural Pattern: Ma Huang, Vasaka and Bala

Step back and the pattern across three independent traditions is striking. Chinese medicine’s ma huang (Ephedra sinica), Ayurveda’s vasaka (Adhatoda vasica), and Ayurveda’s bala (Sida cordifolia, this page’s subject) were all reached for, independently, for the same complaint — difficulty breathing — and all three turn out, on modern analysis, to contain alkaloids with genuine, mechanistically distinct bronchodilator or airway-relevant activity. That is a meaningfully different situation from a traditional claim with no plausible chemistry behind it anywhere on this site. It is also, precisely because the chemistry is real, the reason all three plants carry a serious safety story alongside the respiratory one: ma huang and bala through the adrenergic ephedrine/pseudoephedrine mechanism (see the hub’s Cardiovascular Risk section), and vasaka through its own separate profile (vasicine is a uterine stimulant in animal work, which is why the hub’s Cautions section already flags it as a reason bala is not used in pregnancy).

What This Means for a Reader With Asthma or a Cough

Putting the pieces together: the traditional respiratory use of Sida cordifolia is not an evidence-free folk claim. There is real, partially-quantified pharmacology behind it, running through two separate alkaid families. But that same analysis is the reason this plant is a poor and potentially dangerous choice for a modern reader with a breathing problem:

  1. The dominant, best-quantified bronchodilator alkaloid in this plant is ephedrine — already covered in exhaustive, safety-critical detail on the hub. Concentration is unpredictable from label to label, and ephedrine was specifically withdrawn from asthma therapy because of its cardiovascular effects.
  2. The second bronchodilator alkaloid family, the quinazolines, is real but under-dosed and under-studied in this specific plant. Vasicine is measurably present in the root at a concentration that delivers a fraction of a milligram at traditional doses, has never been tested for bronchodilator effect in Sida cordifolia specifically, and its best pharmacology comes from a different (related) plant and from synthetic derivatives that have not reached the market as drugs.
  3. Asthma is a condition where undertreatment is dangerous. The hub says this and it bears repeating here: substituting an unmeasured oral stimulant, or a compound with no dose-response data, for a modern metered-dose inhaler is a bad trade in a disease where an inadequately controlled attack can be fatal.

If you have asthma, chronic cough or another respiratory condition, the correct next step is your prescribed treatment and your clinician — see Asthma and Pulmonology for what actually treats these conditions.

Evidence Ledger for This Page

  1. Established drug pharmacology, wrong plant for direct evidence. Ephedrine is a genuine, historically-used bronchodilator — but that evidence is for the isolated drug and for ephedra, not for a controlled trial of this plant.
  2. Direct phytochemical quantification — positive and specific. Vasicine is measured, by HPLC, in Sida cordifolia root, at the highest level of eight Sida species tested.
  3. Borrowed pharmacology, clearly labelled. The bronchodilator mechanism for vasicine/vasicinone is established mainly in Adhatoda vasica and in synthetic quinazoline derivatives — not in Sida cordifolia extract itself.
  4. Mechanism ceiling. Sixty-five years of medicinal chemistry on the vasicine scaffold has not produced an approved drug, which bounds how much weight the mechanism can carry.
  5. Absent, not refuted. No bronchodilator assay of Sida cordifolia extract exists. No human pharmacokinetic data for vasicine from any source exists to compare against the traditional-dose arithmetic above.
  6. Refused. A claim that the traditional root dose delivers a “therapeutic” or “subtherapeutic” amount of vasicine, because no human dose-response curve exists to judge it against.
  7. Cross-cultural convergence. Three independent traditions (Chinese, and two Ayurvedic plants) reached for chemically distinct but mechanistically real airway-active alkaloids for the same complaint — genuine supporting pattern, not proof for any one plant.

Key Research Papers

  1. The genus Sida L. – A traditional medicine: its ethnopharmacological, phytochemical and pharmacological data for commercial exploitation in herbal drugs industry. Dinda B et al., Journal of Ethnopharmacology, 2015. General background on the genus. PubMed search
  2. Simultaneous determination of vasicine and vasicinone by High-performance liquid chromatography in roots of eight Sida species. Subramanya MD et al., Ayu, 2016. The direct root-level quantification. PubMed search
  3. Densitometric method for assessment of six specialized metabolites in four Sida sp. and its congener Abutilon indicum. Rahate SP et al., Journal of Pharmaceutical and Biomedical Analysis, 2024. PubMed search
  4. A bronchodilator alkaloid (vasicinone) from Adhatoda vasica Nees. Amin AH, Mehta DR, Nature, 1959. The foundational isolation and demonstration — on the sister genus. PubMed search
  5. Vasicine Attenuates Allergic Asthma by Suppressing Mast Cell Degranulation and Th2 Inflammation via Modulation of the FcεRI/Lyn + Syk/MAPK Pathway. Qu L et al., Pharmaceuticals, 2026. Modern mechanism, also on Adhatoda vasica. PubMed search
  6. Evaluation of pharmacokinetics, pharmacodynamics, and toxicity of potential quinazoline bronchodilators derived from vasicinone. Špulák M et al., Journal of Pharmacology and Experimental Therapeutics, 2025. PubMed search
  7. Synthesis and bronchodilator activity of new quinazolin derivative. Zabeer A et al., European Journal of Medicinal Chemistry, 2006. PubMed search
  8. Synthesis, evaluation and structure-activity relationships of 5-alkyl-2,3-dihydroimidazo[1,2-c]quinazoline… as new potential bronchodilators. Bahekar RH, Rao AR, Arzneimittel-Forschung, 2001. PubMed search
  9. Ephedrae herba: a comprehensive review of its traditional uses, phytochemistry, pharmacology, and toxicology. Zheng Q et al., Journal of Ethnopharmacology, 2023. The parallel Chinese-medicine tradition and its chemistry. PubMed search
  10. Ephedrae Herba and Ephedrine on Nervous System: A Comprehensive Review of Pharmacology and Neurotoxicity. Li J et al., American Journal of Chinese Medicine, 2026. PubMed search
  11. Quality by design-based optimization of Soxhlet extraction and identification of ephedrine by a HPTLC method for Sida rhombifolia and Sida Cordifolia. Imran M et al., Biomedical Chromatography, 2022. Confirms concentration variability across extraction method, echoing the hub’s labelling concern. PubMed search
  12. Sida cordifolia L.: Ethnobotany, Phytochemistry, Phytonanotechnology, and Commercial Application. Kumar S et al., Current Pharmaceutical Biotechnology, 2024. General modern review, also cited on the hub. PubMed search

Connections

Back to Table of Contents